Radius Health, Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company's lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis. Its abaloparatide-SC is under regulatory review in Europe. Its clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis, and the investigational drug RAD1901 for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its preclinical pipeline includes RAD140, which is an orally bioavailable non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under investigation for potential applications in oncology and multiple conditions.